Sublimity Therapeutics Ltd
Albert Agro is the President and CEO of Sublimity Therapeutics Ltd, an Irish-based biotech company developing novel therapeutics in the Inflammatory Bowel Disease therapeutic area. Most recently, Albert was the Chief Medical Officer for Cynapsus Therapeutics, where he was instrumental in initializing the company’s IPO, NASDAQ listing, and $841 million acquisition by Sunovion Pharmaceuticals.
Albert is also the Co-Founder of GRi Bio, a clinical-stage company in NASH. He has held executive positions at Versanum (CEO), Cynapsus (CMO), Ironshore Pharma (CMO), Trillium Therapeutics Inc (CMO), Stem Cell Therapeutics (CMO) and TransTech Pharma (EVP).
He has maintained a position as Professor, Department of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario since September 1996. He is the recipient of a Michael J. Fox Foundation Clinical Scholarship for his work on Apomorphine.